Patti, F <br/><br/>
Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.  [electronic resource] 

 -  Multiple sclerosis (Houndmills, Basingstoke, England)  Jan 2010 
 - 68-77 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1477-0970 
<br/><br/><label>Standard No.: </label>10.1177/1352458509350309  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Cognition Disorders--drug therapy<br/>Cohort Studies<br/>Disability Evaluation<br/>Disease Progression<br/>Dose-Response Relationship, Drug<br/>Endpoint Determination<br/>Female<br/>Humans<br/>Immunologic Factors--therapeutic use<br/>Injections, Subcutaneous<br/>Interferon beta-1a<br/>Interferon-beta--administration & dosage<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Multiple Sclerosis, Relapsing-Remitting--complications<br/>Neuropsychological Tests<br/>Prospective Studies<br/>Survival Analysis<br/>Young Adult